We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Money problems experienced by elderly customers can be red flags for families and institutions alike
For all its landmark status, lecanemab may end up representing a triumph of hope over evidence
Committees cite inappropriate collaboration between FDA and drugmaker
Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s
Dementia drug development, diagnostics and delivery still require much more investment
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Shares fall 11% following two patient deaths in trials of lecanemab
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease
Access to large data sets means predictions are far more accurate in reducing risk
Researchers focus on pathogens including Covid, herpes and Epstein-Barr virus
Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease
Study of Eisai treatment will be one of last chances to prove amyloid hypothesis, say experts
Study could be used to help boost cognitive performance of people developing Alzheimer’s disease
Long-term effects are generally less in children, although infection doubles risk of epilepsy
Scientists are trying to understand the cause of neurological effects and whether symptoms will be long-lasting
FDA’s green light for aducanumab may delay development of more effective treatments for dementia, critics say
Agency that controls spending by government health schemes will not fund drug for most patients
Practical and reassuring tale written with eloquence and insight about a disease which for years was presumed to rob sufferers of sentience
Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m
Experts point to mounting evidence that the virus can cause long-term brain damage in some patients
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
Research to focus on future health burden as variants and looser restrictions drive up cases
US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
International Edition
